Chugai Pharmaceutical Co., Ltd.
CHGCF
Other OTC46.03
USD
-3.12
- -
ISIN
JP3519400000
Return %
Stock
S&P500
1Y
-8.35
26.53
3Y
68.67
76.60
5Y
13.93
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Osamu Okuda
- Full Time Employees
- 5,026
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 2-1-1 Nihonbashi-Muromachi Chuo Japan 103-8324
- IPO Date
- Aug 3, 2012
- Website
- chugai-pharm.co.jp
- Similar Companies
- Business
- Chugai Pharmaceutical Co., Ltd. Chugai Pharmaceutical Co., Ltd. (CHGCF) is a research and development-focused pharmaceutical company that engages in the research, development, manufacturing, marketing, importation, and exportation of prescription pharmaceuticals, primarily in oncology, immunology, neurology, nephrology, and other specialty areas; its main products include oncology offerings such as Alecensa (alectinib, ALK inhibitor), Avastin (bevacizumab, anti-VEGF humanized monoclonal antibody), Herceptin (trastuzumab, anti-HER2 humanized monoclonal antibody), Kadcyla (trastuzumab emtansine, anti-HER2 antibody-tubulin polymerization inhibitor conjugate), Lunsumio (mosunetuzumab, anti-CD20/CD3 humanized bispecific antibody), Perjeta (pertuzumab, anti-HER2 humanized monoclonal antibody), Phesgo (pertuzumab, trastuzumab and vorhyaluronidase alfa combination), Polivy (polatuzumab vedotin, antimicrotubule binding anti-CD79b monoclonal antibody), and Tecentriq (atezolizumab, anti-PD-L1 humanized monoclonal antibody), as well as specialty products like Actemra (tocilizumab, humanized anti-human IL-6 receptor monoclonal antibody), CellCept (mycophenolate mofetil, immunosuppressant), Edirol (eldecalcitol, osteoporosis agent), Enspryng (satralizumab, pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody), Evrysdi (risdiplam, spinal muscular atrophy agent), Hemlibra (emicizumab, anti-coagulation factor IXa/X humanized bispecific monoclonal antibody), Mircera (epoetin beta pegol, long-acting erythropoiesis-stimulating agent), PiaSky (crovalimab, pH-dependent binding humanized anti-complement C5 monoclonal antibody), Tamiflu (oseltamivir, anti-influenza agent), and Vabysmo (faricimab, anti-VEGF/anti-Ang-2 bispecific antibody), supported by advanced antibody engineering technologies and genomic profiling tools like FoundationOne CDx. Founded in 1925 and headquartered in Tokyo, Japan, the company operates domestically through manufacturing and R&D in Japan and internationally with sales and production in Europe, China, Taiwan, South Korea, and over 110 countries approving its products, functioning as a subsidiary of Roche Holding Ltd. with a strategic alliance since 2002 that enhances its global R&D and market access. Recent developments include a collaboration and license agreement with Rani Therapeutics in October 2025 for up to $1.085 billion to develop oral biologics using RaniPill technology for rare diseases and immunology, targeting multiple high-value therapeutics; the acquisition of Renalys Pharma, Inc. announced on October 24, 2025, for approximately 15 billion yen upfront plus earn-outs to secure exclusive rights to sparsentan (FILSPARI) for IgA nephropathy in Japan, South Korea, and Taiwan, followed by a planned absorption-type merger effective December 29, 2025, to integrate operations and accelerate kidney disease pipeline advancement alongside its existing sefaxersen project.
Chugai Pharmaceutical Co., Ltd. (CHGCY) Q1 2026 Earnings Call Transcript
Chugai Pharmaceutical Co., Ltd. (CHGCF) Q2 2025 Earnings Call Transcript
Chugai Pharmaceutical Co., Ltd. (CHGCF) Q4 2024 Earnings Call Transcript
Chugai Pharmaceutical Co., Ltd. (CHGCF) Q3 2024 Earnings Call Transcript
Chugai Pharmaceutical Co., Ltd. (CHGCF) Q2 2024 Earnings Call Transcript